美迪西标准展位#43第46届英国非药学药学药学药学耐压试验检测专题讨论会 (The Korean Society of Nonclinical Study, KSNS) 将于2023年11月17-18日为英国庆尚南道举办。此前博览会由英国非药学药学药学药学耐压试验检测科学调查促进会（KSNS）安排，是英国最负盛名和最具引响力的非药学药学药学药学科学调查会仪最为。那个时候根据怪物健康安全能力各个领域研发组织工司的率领者和战略者，及繁多非药学药学药学药学科学调查学者们都将报名我局游戏活动。TFM of Medicilon Chuansha Site邹汉军博士研究生DABT将率领美迪西法国组织到场我局博览会，当我们在标摊#43，充满期待与您的联络！

时间 | October 17-18, 2024
地点 | Gyeongju, South Gyeongsang Province
美迪西展位  | 43，不见不散！

做全国较晚为买家出示数据医学前宠物界实践的CRO有限公司之三，美迪西出示进一步的医学前实践业务于特性，可以出示数据设备的人身体内部疗效学和GLP标淮下的药代扭矩学、很危险性评定实践业务于。到目前为止美迪西已拥用种安全的疗效评定建模技巧，可对神经元毒及靶点类小氧氧氧分子、单抗及双特异抵抗能力等大氧氧氧分子药品、ADC、CAR-T/CAR-NK神经元开展抗肿癌抗癌肿瘤用药出示数据进一步设备的评定。美迪西对很大生物学技术药品和生物学技术药品建立联系了设备研究方案分享技巧和人身体内部外评定技巧，有小氧氧氧分子和大氧氧氧分子生物学技术研究方案分享APP、免疫力研究方案分享工作中站及放射学性拉曼光谱药代扭矩学实践APP等，兼容最早期需求、成药理作用评定和IND上报等。美迪西拥用经在我国NMPA证书的GLP监理资质，且用了芬兰FDA的GLP场所查，出示复合知名标淮的GLP工作体系，并有AAALAC证书，实践宠物界管理制度质标淮有知名认为。至202几年6月底，美迪西所为世界超2000家买家出示数据药品科研业务于，参于科研完毕的抗癌肿瘤用药及仿制药建设项目已经有490件IND应用医学，与全国外优秀买家联合发展。

KSNS现场美迪西专家

邹汉军医学博士 TFM of Medicilon Chuansha SiteDr. Hanjun Zou is currently the Testing Facility Management for Medicilon Chuansha site in Shanghai. Dr. Zou joined Medicilon in March 2023 as Senior Director in which he led the team or as the study director to be responsible for the overall planning and implementation of the nonclinical study programs, including but not limited to the IND/NDA package design, selection of species, dose determination, protocol design, results interpretation, report drafting and communication with regulatory agencies. The type of drugs he supported included small molecule chemicals, peptide, fusion protein, oligonucleotide, single/bispecific antibodies, ADC, CGT product etc. Before joining Medicilon, Dr. Zou has more than 16 years of experience in toxicity and preclinical safety assessment with most career working in multinational companies. Dr. Zou is also a certified toxicologist (DCST, ERT & DABT) in China, Europe and the United States.

美迪西非临床研究服务

Medicilon's state-of-the-art preclinical facilities hold full AAALAC accreditation. With advanced platforms and experienced scientists, Medicilon guarantees the utmost professionalism in drug efficacy and safety assessments services, adhering to global regulatory standards. Offering services from stand-alone preclinical studies to comprehensive IND-enabling packages, Medicilon provides flexible solutions to efficiently support biotech and pharmaceutical clients in reaching their developmental milestones. Medicilon's Preclinical Research Division services include the following for small molecules, biologics and medicinal herbs: Pharmacology, Pharmacodynamics, ADME, DMPK, Bioanalysis, Drug Safety Evaluation. Medicilon maintains a large in-house library of animal disease models to meet the research demands in different therapeutic areas.  Medicilon can also assist clients in the preparation of a preclinical safety evaluation package.

Pharmacology 

❖Tumor Animal Models (400+) 
❖Non-tumor Animal Models (270+)

DMPK & Bioanalysis

❖In Vitro ADMET 
❖In Vivo PK & Tox

Preclinical Safety Assessment (GLP & non-GLP) 

❖Single and repeated-dose toxicity studies
 ❖Reproductive/developmental and juvenile toxicity studies
 ❖Genotoxicity studies
 ❖Toxicokinetic studies
 ❖Safety pharmacology research
 ❖Immunogenicity studies
 ❖Local tolerance studies
 ❖Carcinogenicity studies

预约商务洽谈